Eisai eyes fiscal 2025 U.S. approval for home version of Alzheimer's drug / Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says / European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai / Japan's Eisai aims for 2030 U.S. release of new Alzheimer's drug / Eisai to offer Alzheimer's drug in China from July / Eisai seeks expanded use of Alzheimer's drug for prevention / After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Eisai.Eu

3 days ago

Bookmark

Share

Eisai.Eu is a company. It is located in Hatfield, the United Kingdom. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.

Key facts

city: Hatfield
country: United Kingdom
employees: Try Pro to see estimate
revenues: Try Pro to see estimate
sector: Health Care
industry: Pharmaceuticals
ESG score: Try Pro to see estimate

See more facts

LinkedIn: 14K followers

Extract data

Download datasets about Eisai.Eu:

Stocks from Eisai.Eu:

Eisai.Eu is one of the companies in the United Kingdom, companies in Pharmaceuticals, companies in Health Care and 3,584,319 companies in our database.

Talking Points

Eisai Europe
Our work at Eisai prioritises patients and their families through our focus to continually improve the benefits that health care can provide.
Welcome to the Eisai EMEA. Eisai (pronounced 'ā-zī') is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. Eisai is one of the world's leading research-based pharmaceutical companies.

Related

Connected or similar to Eisai.Eu: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.